Literature DB >> 21988672

Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy.

S Theilade1, M Lajer, A Jorsal, L Tarnow, H-H Parving, P Rossing.   

Abstract

AIMS: Placental growth factor is a vascular endothelial growth factor involved in angiogenesis, vascular inflammation and plaque formation. Soluble Fms-like tyrosine kinase 1 is a decoy receptor for placental growth factor, reducing its activity. The aim of this study is to evaluate the predictive value of placental growth factor and soluble Fms-like tyrosine kinase 1 in relation to all-cause and cardiovascular mortality and decline in kidney function in Type 1 diabetes.
METHODS: This was a prospective, observational follow-up study with 8 (0-13) years [median (range)] of follow-up, including patients with Type 1 diabetes, of whom 458 had diabetic nephropathy [278 men; age 42 ± 11 years (mean ± sd), diabetes duration 28 ± 9 years, glomerular filtration rate 76 ± 33 ml min(-1) 1.73 m(-2) ] and 442 had long-standing normoalbuminuria (234 men; age 45 ± 12 years, diabetes duration 28 ± 10 years).
RESULTS: Placental growth factor and soluble Fms-like tyrosine kinase 1 levels measured at baseline were higher in patients with diabetic nephropathy compared with patients with long-standing normoalbuminuria [median (range)] 15 (4-131) vs. 11 (7-64) ng/l, (P < 0.001) and 86 (42-3462) vs. 77 (43-1557) ng/l (P < 0.001), respectively. In patients with diabetic nephropathy, high levels of placental growth factor predicted all-cause and cardiovascular mortality [hazard ratio 1.94 (1.16-3.24) and hazard ratio 2.91 (1.45-5.85)] after adjustment for sex, age, smoking, systolic blood pressure, HbA(1c) , cholesterol, glomerular filtration rate and previous cardiovascular disease. High levels of placental growth factor predicted increased risk of end-stage renal disease [hazard ratio 2.77 (1.47-5.14)], but covariate adjustments attenuated the association [hazard ratio 1.89 (0.91-3.95)]. Among patients with long-standing normoalbuminuria, placental growth factor levels predicted fatal and non-fatal cardiovascular events [hazard ratio 1.97 (1.03-3.76)], but not all-cause mortality. Baseline soluble Fms-like tyrosine kinase 1 levels did not predict outcome in either group after adjustment.
CONCLUSION: Placental growth factor is elevated in patients with Type 1 diabetes and diabetic nephropathy and predicts all-cause and cardiovascular mortality, but not deterioration of kidney function.
© 2011 The Authors. Diabetic Medicine © 2011 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21988672     DOI: 10.1111/j.1464-5491.2011.03482.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  7 in total

Review 1.  Smoking as a risk factor for diabetic nephropathy: a meta-analysis.

Authors:  Sensen Su; Wanning Wang; Tao Sun; Fuzhe Ma; Yue Wang; Jia Li; Zhonggao Xu
Journal:  Int Urol Nephrol       Date:  2017-06-19       Impact factor: 2.370

2.  Angiogenic Factors and Risks of Technique Failure and Cardiovascular Events in Patients Receiving Peritoneal Dialysis.

Authors:  Masaru Matsui; Ken-Ichi Samejima; Yukiji Takeda; Katsuhiko Morimoto; Miho Tagawa; Kenji Onoue; Satoshi Okayama; Hiroyuki Kawata; Rika Kawakami; Yasuhiro Akai; Hiroyuki Okura; Yoshihiko Saito
Journal:  Cardiorenal Med       Date:  2016-03-31       Impact factor: 2.041

3.  Association of vascular endothelial factors with cardiovascular outcome and mortality in chronic kidney disease patients: a 4-year cohort study.

Authors:  Mehdi Rambod; Gunnar H Heine; Sarah Seiler; Elizabeth A Dominic; Kyrill S Rogacev; Rama Dwivedi; Ali Ramezani; Maria R Wing; Richard L Amdur; Danilo Fliser; Dominic S Raj
Journal:  Atherosclerosis       Date:  2014-08-12       Impact factor: 5.162

4.  Placental Growth Factor as a Predictor of Cardiovascular Events in Patients with CKD from the NARA-CKD Study.

Authors:  Masaru Matsui; Shiro Uemura; Yukiji Takeda; Ken-Ichi Samejima; Takaki Matsumoto; Ayako Hasegawa; Hideo Tsushima; Ei Hoshino; Tomoya Ueda; Katsuhiko Morimoto; Keisuke Okamoto; Sadanori Okada; Kenji Onoue; Satoshi Okayama; Hiroyuki Kawata; Rika Kawakami; Naoki Maruyama; Yasuhiro Akai; Masayuki Iwano; Hideo Shiiki; Yoshihiko Saito
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

5.  Plasma Placental Growth Factor Concentrations Are Elevated Well in Advance of Type 2 Diabetes Mellitus Onset: Prospective Data From the WHS.

Authors:  Edward K Duran; Nancy R Cook; Maria Bobadilla; Eunjung Kim; JoAnn E Manson; Julie E Buring; Paul M Ridker; Aruna D Pradhan
Journal:  J Am Heart Assoc       Date:  2019-07-19       Impact factor: 5.501

6.  Impact of Obstructive Sleep Apnea on the Levels of Placental Growth Factor (PlGF) and Their Value for Predicting Short-Term Adverse Outcomes in Patients with Acute Coronary Syndrome.

Authors:  Antonia Barcelo; Josep Miquel Bauça; Aina Yañez; Laura Fueyo; Cristina Gomez; Monica de la Peña; Javier Pierola; Alberto Rodriguez; Manuel Sanchez-de-la-Torre; Jorge Abad; Olga Mediano; Jose Amilibia; Maria Jose Masdeu; Joaquin Teran; Josep Maria Montserrat; Mercè Mayos; Alicia Sanchez-de-la-Torre; Ferran Barbé
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

Review 7.  Endogenous Antiangiogenic Factors in Chronic Kidney Disease: Potential Biomarkers of Progression.

Authors:  Katsuyuki Tanabe; Yasufumi Sato; Jun Wada
Journal:  Int J Mol Sci       Date:  2018-06-24       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.